聚合N-胺基氧化 (NO) 捐赠者的最新进展及其治疗应用
Anushree Mondal1, Soumya Paul1, Priyadarsi De1
1Polymer Research Centre and Centre for Advanced Functional Materials, Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, Nadia, West Bengal 741246, India.
Biomacromolecules
|August 8, 2024
概括
聚合物N-胺是新型的氧化 (NO) 捐赠剂,具有增强的稳定性和生物医学应用的向输送. 本综述探讨了它们的设计,合成和治疗潜力,为基于NO的先进疗法铺平了道路.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氧化 (NO) 是一种关键的气传递物,参与血管扩张,心脏功能和血栓形成的预防.
- NO在癌症治疗和抗微生物应用中也表现出潜力.
- 开发有效的氧化捐赠者是利用这些治疗效益的关键.
研究的目的:
- 审查聚合N-胺胺作为氧化捐赠物的设计,合成和生物应用.
- 要突出聚合物N-胺胺相对于小分子对应物的优势.
- 为未来开发先进的基于NO的治疗方法提供N-尼托胺的全面概述.
主要方法:
- 文献综述侧重于聚合物和小分子N-尼托胺.
- 对NO释放的N-尼托拉胺设计策略的分析.
- 评估生物应用和治疗潜力.
主要成果:
- 与小分子相比,聚合物N-胺胺提供了更好的稳定性,更高的NO有效载荷和有针对性的输送.
- 在光照辐射后,N-尼托拉胺可以释放NO,从而实现可控的治疗效果.
- 讨论了各种治疗应用,包括癌症治疗和抗微生物策略.
结论:
- 聚合物N-尼托胺是一种有前途的NO捐赠体,具有显著的治疗潜力.
- 这些材料的进一步开发可能会导致下一代基于NO的药物具有增强性质.
- 本综述为未来对聚合物N-尼托胺开发的研究提供了基础.
相关概念视频
Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Antihypertensive Drugs: Vasodilators
492
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492
Antianginal Drugs: Nitrates and β-Blockers
557
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
557
2° Amines to N-Nitrosamines: Reaction with NaNO2
4.1K
Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
4.1K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
140
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
140
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164


